Exelixis Inc. Stock
Exelixis Inc. Stock
The price for the Exelixis Inc. stock decreased slightly today. Compared to yesterday there is a change of -€0.070 (-0.180%).
With 30 Buy predictions and 1 Sell predictions Exelixis Inc. is one of the favorites of our community.
With a target price of 42 € there is a slightly positive potential of 10.24% for Exelixis Inc. compared to the current price of 38.1 €.
So far the community has only identified positive things for Exelixis Inc. stock. The most positive votes were given for criterium "Worthwhile Investment for the next years".
Pros and Cons of Exelixis Inc. in the next few years
Pros
?
G***** c******* t* c**********
?
W********* I********* f** t** n*** y****
?
M***** P*******
Cons
?
C******** o* t** e**********
?
S********** s********
?
B****
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Exelixis Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Exelixis Inc. | -0.180% | 0.537% | 6.423% | 16.333% | -0.428% | 123.124% | 86.915% |
| Ligand Pharmaceuticals | 5.050% | 4.211% | 11.864% | 107.330% | 19.277% | 182.857% | 63.704% |
| United Therapeutics | -1.160% | -3.219% | 3.308% | 88.659% | 13.293% | 134.886% | 176.629% |
| Ionis Pharmaceuticals Inc. | -1.860% | -2.798% | -0.509% | 139.159% | -7.975% | 91.195% | 77.117% |
Comments
Exelixis (NASDAQ:EXEL) was upgraded by analysts at Wall Street Zen from a "buy" rating to a "strong-buy" rating.
Show more
Ratings data for EXEL provided by MarketBeat
Exelixis (NASDAQ:EXEL) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $52.00 price target on the stock.
Show more
Ratings data for EXEL provided by MarketBeat
Exelixis (NASDAQ:EXEL) had its price target raised by analysts at HC Wainwright from $49.00 to $52.00. They now have a "buy" rating on the stock.
Show more
Ratings data for EXEL provided by MarketBeat
News
3 Under-the-Radar Healthcare Stocks Worth Adding to Your Watchlist
A few healthcare companies garner much of the attention in the sector. The list includes Eli Lilly, Johnson & Johnson, UnitedHealth Group, and several others. However, beyond those giants, there are
Exelixis: A Strong Contender in the Cancer Drug Market
Explore the exciting world of Exelixis (NASDAQ: EXEL) with our contributing expert analysts in this Motley Fool Scoreboard episode. Check out the video below to gain valuable insights into market
3 Reasons Exelixis Stock Could Deliver Market‑Beating Returns Over the Next Decade
Exelixis (NASDAQ: EXEL) is a relatively small biotech company with big dreams -- to become, as its executives said at a presentation in December, a "top five solid tumor oncology company."
The